Skip to main content

Georgina Arrambide García

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Georgina Arrambide García

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Caracterización de pacientes con esclerosis múltiple muy activa y evaluación del efecto de tratamientos de alta efectividad en la evolución de su enfermedad.

IP: Georgina Arrambide García
Collaborators: Jordi Rio Izquierdo, Joaquin Castillo Justribo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 169400
Reference: PI22/01570
Duration: 01/01/2023 - 30/06/2027

Niveles en suero de neurofilamentos de cadena ligera como marcador pronóstico de evolución de la enfermedad y de respuesta al tratamiento en esclerosis múltiple

IP: Georgina Arrambide García
Collaborators: Jordi Rio Izquierdo, Rosalia Horno Ocaña, Cristina Auger Acosta, Joaquin Castillo Justribo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 110715
Reference: PI19/01590
Duration: 01/01/2020 - 30/06/2024

Estudio de la vía visual en pacientes que presentan un síndrome clínico aislado, utilidad clínica y pronóstica

IP: Angela Vidal Jordana
Collaborators: Dulce María Moncho Rodríguez, Georgina Arrambide García, Joaquin Castillo Justribo, Vanessa Carolina Thonon
Funding agency: Instituto de Salud Carlos III
Funding: 77440
Reference: PI17/02162
Duration: 01/01/2018 - 30/06/2022

Papel de los factores hormonales relacionados con la mujer en el riesgo y pronóstico de la E.M.

IP: Mar Tintore Subirana
Collaborators: Susana Otero Romero, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Cristina Auger Acosta, Georgina Arrambide García, Alex Rovira Cañellas, Joaquin Castillo Justribo, Milagros Fraga Pereira
Funding agency: Instituto de Salud Carlos III
Funding: 98615
Reference: PI15/00170
Duration: 01/01/2016 - 31/12/2019

Related news

An international study led by researchers from Vall d’Hebron shows that simple tests that patients can perform themselves help detect changes in disability that may occur even in the absence of disease relapses.

A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Related professionals

Edurne Ruiz Marti

Edurne Ruiz Marti

Research assistant
Infectious Diseases
Read more
Ariadna Campos Martorell

Ariadna Campos Martorell

Senior researcher
Growth and Development
Read more
Javier Hoyo Pérez

Javier Hoyo Pérez

Administration and Management
Neurodegenerative Diseases
Read more
José Manuel Vidal Taboada

José Manuel Vidal Taboada

Main researcher
Peripheral Nervous System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.